Home » Stocks » Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. (ALNA)

Stock Price: $1.54 USD -0.05 (-3.14%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 49.37M
Revenue (ttm) n/a
Net Income (ttm) -43.51M
Shares Out 24.88M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $1.54
Previous Close $1.59
Change ($) -0.05
Change (%) -3.14%
Day's Open 1.60
Day's Range 1.51 - 1.61
Day's Volume 440,195
52-Week Range 0.53 - 6.30

More Stats

Market Cap 49.37M
Enterprise Value 38.33M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.88M
Float 9.23M
EPS (basic) -1.89
EPS (diluted) -1.88
FCF / Share -1.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 435,043
Short Ratio 0.36
Short % of Float 1.72%
Beta 2.91
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.14
Revenue n/a
Operating Income -43.49M
Net Income -43.51M
Free Cash Flow -42.42M
Net Cash 11.04M
Net Cash / Share 0.34
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -68.30%
ROE -176.36%
ROIC -882.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(484.42% upside)
Current: 1.54
Target: 9.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-47.53-35.59-20.95-24.19-13.91
Net Income-47.34-35.65-21.65-24.51-14.25
Shares Outstanding22.1820.744.521.341.26
Earnings Per Share-2.13-1.72-4.80-18.35-11.35
Operating Cash Flow-43.63-31.84-21.07-23.39-13.18
Capital Expenditures-0.12-0.32-0.06-0.100.01
Free Cash Flow-43.75-32.16-21.12-23.50-13.17
Cash & Equivalents30.0161.6494.4948.7669.01
Total Debt10.499.989.399.596.19
Net Cash / Debt19.5251.6685.1139.1762.83
Book Value17.2049.4682.87-59.28-34.97
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allena Pharmaceuticals, Inc.
Country United States
Employees 33
CEO Louis Brenner

Stock Information

Ticker Symbol ALNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALNA
IPO Date November 2, 2017


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.